"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Biotechnology Market size is worth USD 223.8 Billion in 2025 and is projected to reach USD 515.4 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 8.7% from 2026 to 2035. Key trends include expanding biopharmaceutical development, rapid adoption of gene therapies and cell therapies, growing CRISPR and gene editing applications, increasing use of artificial intelligence and computational biology, expansion of contract research and manufacturing services, synthetic biology innovation, advanced sequencing technologies, laboratory automation, and rising strategic collaborations across biotechnology enterprises.

United States Biotechnology Market Overview

The United States Biotechnology Market is witnessing strong growth as pharmaceutical companies, biotechnology organizations, research institutions, healthcare providers, and industrial manufacturers increasingly adopt advanced biological technologies across research, development, manufacturing, and commercialization activities. Biotechnology is supporting innovation across therapeutic development, diagnostics, regenerative medicine, agriculture, industrial manufacturing, environmental applications, and biosecurity.

Biopharmaceuticals continue to represent the largest commercial segment as established biological therapies maintain significant demand across oncology, immunology, neurology, rare diseases, and other chronic and complex conditions. Increasing pharmaceutical investment in monoclonal antibodies, recombinant biologics, vaccines, cell therapies, and gene therapies is creating sustained demand for advanced biotechnology platforms and specialized manufacturing capabilities.

Technological innovation is further supporting market expansion. CRISPR and gene editing, sequencing technologies, synthetic biology, recombinant DNA technology, cell culture, fermentation, and bioinformatics are transforming research productivity and enabling more precise biological engineering. Artificial intelligence and advanced computational tools are increasingly being integrated into discovery, development, manufacturing, and quality management workflows.

Contract research, contract development, and contract manufacturing services are also gaining importance as biotechnology companies seek to reduce capital requirements and accelerate commercialization. Specialized service providers offer validated laboratory infrastructure, clinical development capabilities, analytical testing, and commercial manufacturing capacity, enabling biotechnology innovators to focus resources on scientific development and intellectual property.

Overall, the US Biotechnology Market is expected to experience sustained long term growth as organizations continue investing in advanced biological products, scalable manufacturing platforms, computational biology, gene editing, precision medicine, and integrated digital research ecosystems.

Amgen Enhanced Digital Bioprocess Manufacturing Infrastructure to Improve Biologic Production Efficiency

January 2026 — Amgen enhanced digital bioprocess manufacturing infrastructure to improve operational efficiency across biologic production facilities, reflecting the increasing integration of digital technologies and advanced analytics into commercial biotechnology manufacturing.

Key Takeaways from the Report

Biopharmaceuticals represented more than 39% of total commercial revenue, supported by established therapeutic demand and extensive biological product portfolios.
Gene therapy products are projected to register a CAGR exceeding 11% during the forecast period as precision medicine and genetically targeted interventions expand.
CRISPR based genome engineering adoption expanded by over 30% across commercial development programs, highlighting accelerating investment in advanced gene editing technologies.
Precision medicine initiatives contributed to more than 35% of enterprise biotechnology investments, strengthening demand for genomic, molecular, and computational platforms.
Strategic collaborations represented over 40% of new commercialization initiatives, demonstrating the growing importance of partnerships across biotechnology, pharmaceutical, research, and technology organizations.
Pharmaceutical and biotechnology companies remain major end users due to extensive research pipelines, manufacturing requirements, and continuous investment in biological product development.
Contract research and manufacturing services are gaining importance as biotechnology organizations seek flexible infrastructure, specialized expertise, and improved capital efficiency.
Artificial intelligence, computational biology, laboratory automation, and digital manufacturing technologies are creating new opportunities for biotechnology companies seeking to improve research productivity and commercialization efficiency.

Top Players

Amgen Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Biogen Inc.
Moderna, Inc.
Vertex Pharmaceuticals Incorporated
Illumina, Inc.
Thermo Fisher Scientific Inc.
Bio Rad Laboratories, Inc.
Danaher Corporation
Abbott Laboratories
Pfizer Inc.
Bristol Myers Squibb
Genentech, Inc.
CRISPR Therapeutics AG

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID 19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies. The report evaluates biopharmaceuticals, biosimilars, vaccines, cell therapy products, gene therapy products, tissue engineered products, industrial biotechnology products, agricultural biotechnology products, research reagents and kits, recombinant DNA technology, cell culture technology, CRISPR and gene editing, sequencing technologies, synthetic biology, fermentation technology, bioinformatics, computational biology, monoclonal antibody technology, therapeutics, diagnostics, drug discovery and development, regenerative medicine, and industrial and agricultural biotechnology applications.

Latest Announcement

March 2026 — Gilead Sciences expanded cell therapy manufacturing operations to support increasing commercial treatment demand, strengthening production capabilities for advanced cellular therapies and reinforcing the broader expansion of next generation biotechnology manufacturing infrastructure.